Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #44560 on CYduct Diagnostics Inc (CYDX)
Ask kicker
08/13/12 2:29 PM
#44563 RE: Jamming1 #44560
Solos Endoscopy finished the first quarter of 2012 with a 16% increase in sales as compared to the first quarter of 2011. Going forward, Solos management plans to make a real effort to reduce debt and position the Company for profitability. By working with its various creditors, management believes the Company can be virtually debt free by the 2nd quarter of 2012. Solos’ main focus is to strengthen the Company’s bottom line. Solos is implementing several strategies to accomplish this goal: I. The Company has dramatically reduced its debt, and is now building its asset base through the acquisition of new endoscopic equipment. By focusing on building its inventory of Disposable instruments, the Company can enjoy a faster turnover which will result in increased revenues. Solos Disposables have the highest profit margins of all their various endoscopic instruments. II. Solos Endoscopy will focus on new product development. As discussed above, demand for minimally invasive endoscopic procedures is on the rise globally. Solos believes it must continue to develop new products to meet this demand. Solos plans on working towards the international launch of its product lines as it continues to strengthen its national distribution channels in the United States. This should result in an increase in sales through 2012 and beyond. III. Solos Endoscopy plans on developing new strategic partnerships and joint ventures. Our goal of maintaining a low overhead, with little debt, while expanding our product distribution internationally, means that it is necessary for Solos to look for new partnerships with Company’s who are willing to share the cost of both new product development and distribution. This strategy should result in a positive bottom line and real value for all shareholders.